Immunovant Phase 3 Batoclimab Thyroid Eye Disease 2022

Immunovant's investor presentation outlining Phase 3 clinical trial plans for batoclimab in thyroid eye disease (TED). The company plans to initiate two parallel, placebo-controlled Phase 3 trials in 2022, each enrolling approximately 100 subjects, with topline results expected in the first half of 2025. The presentation emphasizes FDA alignment and the differentiated clinical benefit potential of batoclimab in this indication.